Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

CONTEXT: Prostate cancer remains highly prevalent and has a poor clinical outcome once metastatic. Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T treatment extends survival but is independent of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulders, Peter F., De Santis, Maria, Powles, Thomas, Fizazi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456994/
https://www.ncbi.nlm.nih.gov/pubmed/26025563
http://dx.doi.org/10.1007/s00262-015-1707-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456994/
https://www.ncbi.nlm.nih.gov/pubmed/26025563
http://dx.doi.org/10.1007/s00262-015-1707-3

Ejemplares similares